Why Is Astrazeneca Willing To Spend a Whopping $12.1 Billion?
Neratinib Included In NCCN Guidelines For Specific HER2-Negative Breast Cancers
New Targeted Drug For Leukaemia Approved, 35% Of Patients' Cancer Cells Disappear Completely!
Another Cancer-Independent Targeted Drug Approved! Up To 84% Efficacy!
New Treatment For Uroepithelial Carcinoma Receives Fda Fast Track Designation With Encouraging Initial Results
Genetic Modification Of Immune Cells To Make Them Tireless, Cold-Blooded "Cancer Cell Killers"!
